Education
About Us
Working with TipRanks
Follow Us
Bluejay Diagnostics (BJDX)
NASDAQ:BJDX
BJDX Stock Chart & Stats
$1.97
-$0.20(-5.19%)
At close: 4:00 PM EST
$1.97
-$0.20(-5.19%)
Day’s Range― - ―
52-Week Range$1.26 - $12.45
Previous CloseN/A
Volume34.54K
Average Volume (3M)5.27M
Market Cap
$4.19M
Enterprise Value-$849.88K
Total Cash (Recent Filing)$4.44M
Total Debt (Recent Filing)$165.38K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Apr 16, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-685.13
Shares Outstanding1,494,182
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-0.20
Enterprise Value/Revenue-3.93
Enterprise Value/Gross Profit23.75
Enterprise Value/Ebitda0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bluejay Diagnostics News
BJDX FAQ
What was Bluejay Diagnostics’s price range in the past 12 months?
Bluejay Diagnostics lowest stock price was $1.26 and its highest was $12.45 in the past 12 months.
What is Bluejay Diagnostics’s market cap?
Bluejay Diagnostics’s market cap is $4.19M.
When is Bluejay Diagnostics’s upcoming earnings report date?
Bluejay Diagnostics’s upcoming earnings report date is Apr 16, 2025 which is 202 days ago.
How were Bluejay Diagnostics’s earnings last quarter?
Bluejay Diagnostics released its earnings results on Nov 07, 2024. The company reported -$7.754 earnings per share for the quarter, missing the consensus estimate of N/A by -$7.754.
Is Bluejay Diagnostics overvalued?
According to Wall Street analysts Bluejay Diagnostics’s price is currently Overvalued.
Does Bluejay Diagnostics pay dividends?
Bluejay Diagnostics does not currently pay dividends.
What is Bluejay Diagnostics’s EPS estimate?
Bluejay Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bluejay Diagnostics have?
Bluejay Diagnostics has 1,494,182 shares outstanding.
What happened to Bluejay Diagnostics’s price movement after its last earnings report?
Bluejay Diagnostics reported an EPS of -$7.754 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.15%.
Which hedge fund is a major shareholder of Bluejay Diagnostics?
Currently, no hedge funds are holding shares in BJDX
Company Description
Bluejay Diagnostics
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Technical Analysis
Aethlon Medical
―
Venus Concept
―
Bone Biologics
―
Tivic Health Systems
―
DIH Holdings US, Inc Class A
―
Ownership Overview
―
Insiders
0.28% Mutual Funds
6.43% Other Institutional Investors
93.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---